

SHCP APC Summary

Date: November 2024

(Applications were approved virtually via FutureNHS platform)

The Link to previous SHCP APC minutes are available [HERE](#)

For access to the Sussex Partner Formulary [Welcome to The Sussex Partner Formulary](#)

SHCP APC item	Virtually approved
To include ustekinumab originator brand Stelara and biosimilar brands Pyzchiva, Steqeyma, Uzpruvo and Wezenla on the formulary with RED colour-coding for use in accordance with approved NICE TA	Approved RED formulary coding
Lithium Shared Care Protocol (SCP) , for patients within adult services. All new patients to be initiated onto this new SCP.	Approved Shared care - Sussex Health & Care (ics.nhs.uk)
DOAC Selection pathway and FAQ document.	Approved Atrial fibrillation DOAC pathway and FAQ - NHS Sussex
NICE Technology Appraisals	
NICE TA999 Vibegron for treating symptoms of overactive bladder syndrome	Approved GREEN formulary coding
NICE TA1000 Iptacopan for treating paroxysmal nocturnal haemoglobinuria	Approved RED formulary coding
NICE TA1001 Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment	Approved RED formulary coding
NICE TA1002 Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over	Approved RED formulary coding
NICE TA1003 Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over	Approved RED formulary coding
NICE TA 1004 Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion	Approved RED formulary coding
NICE TA1005 Futibatinib for previously treated advanced	Approved RED formulary coding

cholangiocarcinoma with FGFR2 fusion or rearrangement	
NICE TA1007 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Approved RED formulary coding
NICE TA1008 Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments	Approved RED formulary coding
NICE TA1009 Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension	Approved PURPLE formulary coding
NICE TA1010 Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria	Approved RED formulary coding
NICE TA1011 Belzutifan for treating tumours associated with von Hippel-Lindau disease	Approved RED formulary coding
NICE TA1013 Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Approved RED formulary coding
HST8 Burosumab for treating X-linked hypophosphataemia in children and young people	For noting, no further action
NICE Guidelines	
NG148 Acute kidney injury: prevention, detection and management	Reviewed by ICB Therapeutic Leads and confirmed all local prescribing positions are compliant.
New BlueTeq forms	
November 2024	
Faricimab – Macular oedema after retinal vein occlusion (TA1004) – Initiation form Faricimab – Macular oedema after retinal vein occlusion (TA1004) - continuation form Abaloparatide – osteoporosis after menopause (TA991) – application form	
Discontinuations	
December 2026	Levemir Penfill
December 2026	Levemir Flexpen
March 2025	Insulatard Isophane
March 2025	NovoRapid Flexpen
July 2025	Trandate 50mg tablets (RPH Pharmaceuticals AB) (Labetalol)
October 2024	Trandate 400mg tablets (RPH Pharmaceuticals AB) (Labetalol)
October 2024	NovoRapid (insulin aspart) FlexTouch100units/ml solution for injection 3ml pre-filled pens
September 2024	Calcium 500mg effervescent tablets

October 2024	Ketoprofen 100mg and 200mg MR Capsules
September 2024	Macrogol compound oral liquid NPF sugar free
October 2024	Novo Nordisk Victoza (liraglutide) 6mg/mL pre-filled injection
January 2025	Fusidate (Fucidin) 250mg tablets and
June 2025	Fusidic acid (Fucidin) 250mg/5ml oral suspension

Formulary status definitions Drug Status Key	
<ul style="list-style-type: none"> • Non-Specialist Drugs • Specialist recommendation (or initiation where noted) • Specialist Initiation WITH Shared Care Guidelines 	<ul style="list-style-type: none"> • Specialist ONLY Drugs • Mixed Status - See individual drug entries for more details